Beacon says gene therapy succeeds in key trial of rare eye disease XLRP
Beacon Therapeutics has succeeded in a genetic eye disease where large drugmakers including Johnson & Johnson and Biogen have failed. On Monday, Beacon said its gene therapy for X-linked retinitis pigmentosa (XLRP) passed a Phase ...
Syncona's shares surged by approximately 6% on Monday following Beacon Therapeutics' announcement that its gene therapy for a rare inherited eye disease, X-linked retinitis pigmentosa (XLRP), met its primary endpoint in a late-stage trial. The VISTA trial, which tested laruparetigene zovaparvovec (laru-zova), involved 85 male patients aged 12 to 48 with XLRP caused by RPGR gene mutations.
At 12 months, the trial showed that 31% of patients receiving the high dose and 24.1% of those receiving the low dose improved by at least 15 letters in low-luminance visual acuity, compared to none in the untreated control group. Beacon plans to initiate discussions with global regulators and commence a rolling Biologics License Application later this year.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Syncona jumps 6% after Beacon gene therapy trial success investing.com
